Regeneron Beats Second-Quarter Expectations as Dupixent Growth Fuels Strong Results

Medical probe investigating ©rawpixel

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported stronger-than-expected second-quarter results, comfortably surpassing Wall Street forecasts for some net and revenue. The company's show was driven by continued momentum crossed its commercialized portfolio, led by beardown maturation successful Dupixent, helping assistance its shares much than 3% successful premarket trading connected Thursday.

The biotechnology institution besides updated its full-year fiscal guidance pursuing the quarter.

Earnings and Revenue Outperform Forecasts

Regeneron posted adjusted net of $14.29 per stock for the 2nd quarter, exceeding analysts' statement estimation of $10.58.

Revenue totaled $4.29 billion, up of the expected $3.8 cardinal and up 17% from $3.68 cardinal successful the aforesaid 4th past year.

Growth was supported by beardown income crossed respective of the company's starring therapies.

Global Dupixent nett sales, reported by Sanofi, accrued 38% twelvemonth implicit twelvemonth to $6.0 billion.

In the United States, EYLEA HD generated nett income of $596 million, representing a 52% increase, portion planetary income of Libtayo climbed 30% to $489 million.

Dupixent Partnership Continues to Drive Growth

"Regeneron delivered different 4th of beardown fiscal performance, with double-digit top- and bottom-line maturation reflecting the continued spot of our commercialized portfolio and the imaginable of our pipeline," said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer.

Revenue from Regeneron's collaboration with Sanofi roseate 51% to $2.17 cardinal during the quarter, chiefly reflecting higher profits generated from Dupixent sales.

The institution besides announced that it afloat repaid the Sanofi Development Balance by the extremity of the 2nd quarter, a milestone expected to summation collaboration profits opening successful the 3rd quarter.

Company Updates 2026 Guidance

Regeneron revised respective elements of its fiscal outlook for 2026.

The institution present expects adjusted probe and improvement expenses to scope betwixt $5.95 cardinal and $6.05 billion, compared with its erstwhile forecast of $5.90 cardinal to $6.10 billion.

Adjusted selling, wide and administrative expenses are present projected to beryllium betwixt $2.50 cardinal and $2.60 billion, narrowing the anterior guidance scope of $2.50 cardinal to $2.65 billion.

Regeneron besides raised its adjusted gross borderline forecast connected nett merchandise income to betwixt 84% and 85%, up from its erstwhile anticipation of 83% to 84%.

Regeneron Pharmaceuticals banal terms